Peposertib (M3814)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Peposertib (M3814), covering 2026-04-13 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer [Phase 1]